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ABSTRAK
Kami laporkan 2 orang pasien dengan limfoma dan rabdomiosarkoma dengan metastasis paru yang 
mengalami pneumotoraks spontan setelah kemoterapi. Kasus 1, seorang pria berusia 43 tahun, datang dengan 
keluhan sesak napas 10 hari sebelum masuk rumah sakit. Tidak ada riwayat trauma atau terapi tuberkulosis 
sebelumnya. Tiga minggu sebelumnya pasien mendapat kemoterapi CHOP siklus pertama untuk limfoma non 
Hodgkin’s stadium II BE. Pada foto toraks didapatkan adanya pneumotoraks kanan.  Setelah mendapat terapi 
dengan pemasangan chest tube thoracotomy (CTT) selama 1 bulan, pasien mengalami perbaikan dan kemoterapi 
dilanjutkan tanpa komplikasi lebih lanjut. Kasus 2, seorang pria 35 tahun datang dengan keluhan sesak napas 
dan nyeri dada pada hari keempat setelah kemoterapi sistemik siklus kedua untuk rabdomiosarkoma stadium IV 
(metastasis paru) dengan doksorubisin, ifosfamid, mesna, dan dacarbazin. Foto toraks memperlihatkan adanya 
hidropneumotoraks bilateral. Setelah terapi dengan pemasangan CTT selama 2 minggu, pasien mengalami 
perbaikan dan kemoterapi dilanjutkan tanpa komplikasi lebih lanjut.
Mekanisme pneumotoraks yang terjadi setelah kemoterapi belum jelas diketahui. Terdapat beberapa 
hipotesis  di antaranya: 1). Pecahnya bula subpleura setelah kemoterapi; 2). Pecahnya bula emfisematosa pada 
bagian paru yang mengembang akibat obstruksi parsial oleh tumor; 3). Tumor lisis atau nekrosis akibat efek 
sitotoksik kemoterapi yang secara langsung menimbulkan pembentukan fistula. Pada pasien dengan keluhan 
sesak napas dan nyeri dada mendadak yang terjadi setelah kemoterapi tumor yang bersifat kemosensitif, perlu 
dipikirkan kemungkinan terjadinya pneumotoraks spontan. Penatalaksanaannya adalah dengan reekspansi 
paru. Pneumotoraks yang diinduksi kemoterapi seharusnya dikelola sebagai kegawatdaruratan onkologi.
Kata kunci: pneumotoraks spontan, kemoterapi, tumor kemosensitif, kegawatdaruratan onkologi.
ABSTRACT
We present 2 patients who developed spontaneous pneumothorax (SP) following rapid regression of lymphoma 
and rhabdomyosarcoma with lung metastases. Case 1, a 43-year old man was admitted to our hospital with dyspnea 
10 days before admission. He denied any recent trauma or previous treatment for lung tuberculosis. Three weeks 
prior to admission, he received first cycle of CHOP for non-Hodgkin’s lymphoma stage II BE. Chest X-ray consistent 
with right pneumothorax. After treatment with chest tube drainage for about 1 month, the patient recovered and 
chemotherapy could be continued without further complications. Case 2, a 35- year old man was admitted to 
other hospital with dyspnea and chest pain on day 4 after second cycle of systemic combined chemotherapy for 
rhabdomyosarcoma stage IV (lung metastases) with doxorubicin, ifosfamide, mesna, and dacarbazine. Chest X-ray 
showed hydropneumothorax on right and left lung. After treatment with chest tube drainage about 2 weeks, the 
patient recovered and chemotherapy could be continued without further complications.
The mechanism of pneumothorax following chemotherapy is not clearly understood yet, however, several 
Vol 48 • Number 2 • April 2016                                                Chemotherapy-induced spontaneous pneumothorax
hypotheses have been considered: 1) the rupture of a subpleural bulla after chemotherapy; 2) the rupture of 
an emphysematous bulla in an over expanded portion of the lung which is partially obstructed by a neoplasm; 
3) tumor lyses or necrosis due to cytotoxic chemotherapy directly induces the formation of fistula. Dyspnea 
and chest pain suddenly appear during successful chemotherapy for metastatic chemosensitive tumors should 
alert the physician to the possibility of SP. The treatment is directed toward lung re-expansion. Chemotherapy 
induced pneumothorax should be considered as oncologic emergency.
Keywords: spontaneous pneumothorax, chemotherapy, chemosensitive tumors, oncologic emergency.
INTRODUCTION
Chemotherapy is one of the modalities 
of cancer treatments. The principal obstacles 
to the clinical efficacy of chemotherapy has 
been toxicity to the normal tissue of the 
body especially rapidly growing cells.1 Many 
side effects of chemotherapy are predictable, 
depending on the drugs in the regimen, and 
can be prevented or easily diagnosed and 
managed effectively without causing substantial 
morbidity. Many of these can cause unpredictable 
and rare side-effects, occurring in fewer than 1% 
of patients, which can develop as immediate life-
threatening illnesses.2 Nowadays, spontaneous 
pneumothorax (SP) caused by chemotherapy has 
been reported sporadically.
SP is generally observed in healthy young 
men, as a result of rupture of apical and/or 
subpleural blebs. Pneumothorax can also occur 
secondary to a variety of pulmonary disorders 
such as chronic obstructive pulmonary disease 
(COPD), pneumoconiosis, diffuse interstitial 
fibrosis, and infection diseases. Iatrogenic 
factors are continuous positive pressure 
ventilation, closed-chest cardiac massage, and 
tracheostomy.3 Although SP is a well known 
complication of primary lung cancer and 
metastatic lung disease, it is a rare complication 
of chemotherapy, with a reported incidence 
of less than 1%, and is commonly associated 
with chemosensitive tumours such as germ-
cell tumours, lymphomas, and sarcomas and 
rarely with lung and gynaecological malignant 
disease.4-5 Pneumothorax seems to occur 2–7 
days after chemotherapy treatment and can be 
unilateral or bilateral.2
These complications should be kept in mind 
in order to avoid further sequelae. A search for the 
presence of intrapleural pathology by a thorough 
clinical and radiological evaluation should be 
made in all patients with unexplained dyspnea 
and chest pain after received chemotherapy. 
Clinicians should be aware that spontaneous 
pneumothorax may be one of the manifestation 
of chemotherapy’s side effect.
CASE ILLUSTRATION
Herein, we present 2 patients who developed 
SP following rapid regression of lymphoma and 
rhabdomyosarcoma with lung metastasis.
Case 1: A 43-year old man was admitted 
to our hospital with complaints of dyspnea and 
productive cough 10 days before admission. 
There were no history of fever, nor recent trauma 
or previous treatment for lung tuberculosis. Three 
weeks prior to admission, he received first cycle 
of CHOP for non-Hodgkin’s lymphoma stage 
II BE.
He had tachypnea and tachycardia. On 
physical examination, we found left tracheal 
deviation, pulmonary examination revealed 
right sided hypersonor percussion notes and 
diminished breath sound on auscultation. 
His chest X-ray was consistent with right 
pneumothorax (Figure 1). Chest X-ray before 
chemotherapy was within normal limit (Figure 
2). Mycobacterium tuberculosis was not detected 
in his sputum. We did not perform a chest 
computed tomography (CT) scan for evaluated 
lung involvement from lymphoma due to 
financial problem.
According to British Thoracic Society 
(BTS) pleural disease guideline 2010, 
patients with primary SP or secondary SP and 
significant breathlessness associated with any 
size of pneumothorax should undergo active 
intervention.6 In this patient, we inserted chest 
tube thoracotomy (CTT) in emergency room. 
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Second cycle of chemotherapy was postponed. 
After treatment with chest tube drainage about 1 
month and chemical pleurodesis was attempted 
using tetracycline, the patient recovered and 
chemotherapy could be continued without further 
complications.
Case 2 : A 35- year old man was admitted to 
other hospital with dyspnea and chest pain on 
day 4 after second cycle of systemic combined 
chemotherapy for rhabdomyosarcoma of the 
upper left thigh stage IV (lung metastases) 
with doxorubicin, ifosfamide, mesna, and 
dacarbazine. There was no history of fever and 
no reducing dyspnea at rest.
He had tachypnea and tachycardia. On 
physical examination, we found hypersonor on 
percussion and reduced vesicular breath sound on 
the both chest walls, without tracheal deviation. 
His chest X-ray showed hydropneumothorax on 
right and left lung (Figure 3).
Based on BTS pleural disease guideline 
2010,6 we inserted CTT on bilateral hemithorax 
in emergency room. Chest X-ray 24 hours 
after CTT insertion showed complete lung re-
expansion (Figure 4). After treatment with a chest 
tube drainage for about 2 weeks and chemical 
pleurodesis was attempted using tetracycline, 
the patient recovered and chemotherapy could 
be continued without further complications.
Figure 1. Chest X-ray consistent with right pneumothorax.
Figure 2. Chest X-ray before chemotherapy
Figure 3. Chest X-ray on admission
Figure 4. Chest X-ray performed 24 hours after insertion 
chest tube
DISCUSSION
SP in primary pulmonary neoplasm or lung 
metastases is very rare. However, SP seems to 
occur more often in patients with metastases 
from sarcomas, especially osteogenic sarcoma, 
than in patients with primary lung carcinoma.7 
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Conversely, sporadic case reports describe SP 
due to lung metastases from teratomas, Wilms’ 
tumors, melanomas, carcinomas of the kidney and 
pancreas, gynecologic malignancies, lymphomas, 
choriocarcinomas, and lymphangiomatosis.5,7 
The mechanism of pneumothorax following 
chemotherapy is not clearly understood yet, 
however, several hypotheses have been 
considered:4-5,7-10 1) the rupture of a subpleural 
bulla after chemotherapy; or growing nodules 
can cause a check-valve effect, with subsequent 
overdistension of the alveoli, leading to the 
release of air into the interstitial tissues and 
eventual rup¬ture of a subpleural bleb 2) the 
rupture of an emphysematous bulla in an over 
expanded portion of the lung which is partially 
obstructed by a neoplasm; 3) tumor lyses or 
necrosis due to cytotoxic chemotherapy directly 
induces the formation of fistula.
When small airways are narrowed by cancer 
invasion they act as a check valve, causing air 
trapping and dilation of distal alveolar spaces and 
eventual rupture. Bronchopleural fistula can be 
caused by either direct tumor invasion or develop 
secondary to necrosis of a peripheral tumor 
from effective chemotherapy, or spontaneous 
vascular occlusion within the tumor itself. Direct 
invasion of the pleura by tumor is also a possible 
mechanism though relatively uncommon.11 
Pneumothorax following radiation therapy and 
following bleomycin lung have been described. 
It is also possible that tumour invasion and 
disruption of the visceral pleura and of peripheral 
bronchioles might produce slow air leakage 
resulting in small clinically silent pneumothorax.4 
Lee proposed the temporal relationship between 
the use of combination chemotherapy and the 
development of pneumothorax as a consideration 
of chemotherapeutic’s side effects. For example, 
doxorubicin was the chemotherapeutic agent 
most likely to impair the wound healing with 
tissue repair, and may consequently predispose 
patients with pulmonary metastasis or underlying 
lung lesions to pneumothorax.12-13
In case 1, the pathogenesis of the SP may 
have involved the rupture of an emphysematous 
bulla in an over expanded portion of the lung 
which is partially obstructed by a neoplasm 
or tumor lyses or necrosis due to cytotoxic 
chemotherapy directly induces the formation of 
fistula. The mechanism of rupture of a subpleural 
bulla after chemotherapy is ruled out because 
patient is no-affected by COPD according his 
medical history and he denied any recent trauma 
or previous treatment for lung tuberculosis. The 
rupture of an emphysematous bulla in an over 
expanded portion of the lung which is partially 
obstructed by a neoplasm mechanism is likely 
but CT scan and bronchoscopy not be done. 
The likelihood of tumor lyses or necrosis due 
to cytotoxic chemotherapy directly induces the 
formation of fistula mechanism is strengthened 
by responsiveness of the tumor to cytotoxic 
chemotherapy. This type of complication is 
not unique, as rapid shrinkage of abdominal 
lymphoma which is known to lead to perforation 
of the bowel in some patients.5 Based on the 
mechanisms of the SP, it was always associated 
with lung involvement,8 but in present case, lung 
involvement not be evaluated.
In case 2, the pathogenesis of the SP may have 
involved in the rupture of an emphysematous 
bulla in an over expanded portion of the lung 
which is partially obstructed by a neoplasm 
mechanism. Our patient is a non smoker, has no 
previous history of SP and is not manipulated 
in any way, so attachment of the rupture of a 
subpleural bulla after chemotherapy mechanism 
is ruled out. The tumor lyses or necrosis due to 
directly induced formation of fistula mechanism 
of cytotoxic chemotherapy is unlikely, because 
chest X-ray showed no improvement of lung 
metastases after chemotherapy. The possibility 
mechanism of rupture of an emphysematous 
bulla in an over expanded portion of the lung 
which is partially obstructed by a neoplasm is 
more likely. However, we did not performed 
chest CT scan and bronchoscopy to confirm this. 
In both cases, doxorubicin was included in 
the cytotoxic regimen, however it is difficult to 
relate its direct effect on pneumothorax.12 We 
assumed that pneumothorax in our patients were 
triggered by the chemotherapy.
The t reatment  of  SP secondary to 
chemotherapy is directed toward lung re-
expansion. A closed chest tube is usually unable 
to prevent recurrence of pneumothorax in such 
patient and CTT alone results on only partial 
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re-expansion of the lung.5,14 If an experienced 
thoracic surgeon is not available or in case 
patient refuses an operation or the operative risk 
is too high, chemical pleurodesis by instillation 
of a pleural irritant into the thoracic drain or 
by under local anaesthesia is an alternative to 
invasive surgical treatment.3,6 The report of 
the effectiveness of chemical pleurodesis in 
primary SP is well documented. In both our 
cases, chemical pleurodesis with tetracycline 
successfully results in lung re-expansion. This 
treatment was effective and at three months 
follow-up, both the patients have no recurrence 
of pneumothorax.
CONCLUSION
Sudden dyspnea and chest pain appearing 
du r ing  chemothe rapy  fo r  me tas t a t i c 
chemosensitive tumors should alert the physician 
to the possibility of SP. The treatment is directed 
toward lung re-expansion. Chemical pleurodesis 
via chest tube may be an effective treatment 
strategy of pneumothorax. We suggest that 
chemotherapy-induced SP should be included 
in oncologic emergencies and require our 
awareness.
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